A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

Completed · Phase 2

Conditions studied: Acute Myelogenous Leukemia

In brief

This is a phase II study to evaluate the safety, feasibility and efficacy of immunotherapy with GRNVAC1 in patients with AML.

Key facts

Study ID

NCT00510133

Run by

Asterias Biotherapeutics, Inc.

People needed

21

Starts

2007-07-01

Expected to finish

2014-08-01

Last updated by the study team

2019-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• AML in first complete remission (CR1) or in second complete remission (CR2) with CR1 >/= 6 months
• Has completed at least one cycle of consolidation chemotherapy within past 6 months
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Adequate hepatic/renal function

You may not qualify if…

• CR1 and good risk cytogenetic features [t(15;17), t(8;21), inv(16) or t(16:16)]
• Central nervous system or leptomeningeal disease
• Allogeneic stem cell transplant planned or expected
• Documented allergy to penicillin or beta-lactam antibiotics
• Active or ongoing autoimmune disease
• Clinically significant pulmonary or cardiovascular disease

Where it is running

• Emory University School of Medicine — Atlanta, Georgia, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Washington University School of Medicine, Siteman Cancer Center — St Louis, Missouri, United States
• University of Nebraska Medical Center — Omaha, Nebraska, United States
• Ohio State University — Columbus, Ohio, United States
• UT Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.